Literature DB >> 12505693

Dimerization of G protein-coupled receptors: CB1 cannabinoid receptors as an example.

James Wager-Miller1, Ruth Westenbroek, Ken Mackie.   

Abstract

A polyclonal antibody directed towards the last 73 amino acid residues of the rat type 1 cannabinoid (CB1) receptor strongly and exclusively labels a high molecular weight (between 160 and 200 kDa) form of the receptor in Western analysis. In contrast, a human CB1 polyclonal antibody identifies both monomeric CB1 as well as the high molecular weight form. The carboxy terminus (CT) antibody was also used in immunocytochemistry of rat hippocampal sections. Sections probed with CT antibody show intense staining of a meshwork of fibers and occasional interneurons of the stratum oriens, stratum pyramidal, and stratum radiatum of the CA1 and CA3 regions while mossy fibers and granule cells of the internal stratum appear unstained. These data provide evidence that CB1 likely exists as a dimer in vivo and that the carboxy end of the receptor may play a role in the assembly of the oligomer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12505693     DOI: 10.1016/s0009-3084(02)00151-2

Source DB:  PubMed          Journal:  Chem Phys Lipids        ISSN: 0009-3084            Impact factor:   3.329


  43 in total

Review 1.  Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?

Authors:  Tricia H Smith; Laura J Sim-Selley; Dana E Selley
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

2.  Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors.

Authors:  Brian D Hudson; Terence E Hébert; Melanie E M Kelly
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 3.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

4.  mu opioid and CB1 cannabinoid receptor interactions: reciprocal inhibition of receptor signaling and neuritogenesis.

Authors:  Carl Rios; Ivone Gomes; Lakshmi A Devi
Journal:  Br J Pharmacol       Date:  2006-05-08       Impact factor: 8.739

Review 5.  Looking for the role of cannabinoid receptor heteromers in striatal function.

Authors:  Sergi Ferré; Steven R Goldberg; Carme Lluis; Rafael Franco
Journal:  Neuropharmacology       Date:  2008-07-19       Impact factor: 5.250

Review 6.  Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease relevance.

Authors:  Melissa L Perreault; Ahmed Hasbi; Brian F O'Dowd; Susan R George
Journal:  Neuropsychopharmacology       Date:  2013-06-18       Impact factor: 7.853

7.  Neuronal expression of CB2 cannabinoid receptor mRNAs in the mouse hippocampus.

Authors:  Y Li; J Kim
Journal:  Neuroscience       Date:  2015-10-26       Impact factor: 3.590

8.  Toward the Development of Bivalent Ligand Probes of Cannabinoid CB1 and Orexin OX1 Receptor Heterodimers.

Authors:  David A Perrey; Brian P Gilmour; Brian F Thomas; Yanan Zhang
Journal:  ACS Med Chem Lett       Date:  2014-03-25       Impact factor: 4.345

9.  Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signalling.

Authors:  N A Balenga; E Martínez-Pinilla; J Kargl; R Schröder; M Peinhaupt; W Platzer; Z Bálint; M Zamarbide; I G Dopeso-Reyes; A Ricobaraza; J M Pérez-Ortiz; E Kostenis; M Waldhoer; A Heinemann; R Franco
Journal:  Br J Pharmacol       Date:  2014-09-05       Impact factor: 8.739

Review 10.  Signal transduction via cannabinoid receptors.

Authors:  George D Dalton; Caroline E Bass; C G Van Horn; Allyn C Howlett
Journal:  CNS Neurol Disord Drug Targets       Date:  2009-12       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.